Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Clinical characteristics of patients according to the presence or absence of endothelial dysfunction

From: Is arginase a potential drug target in tobacco-induced pulmonary endothelial dysfunction?

Characteristics Smokers p
  ED + (n = 11) ED (n = 18)  
Age, years (median, range) 63 (44–77) 62 (48–78) 0.86
Male:Female ratio 7:4 16:2 0.11
Tobacco, pack-years (mean, range) 54 (30–120) 46 (10–90) 0.74
Current smokers (n=) 5 10 0.96
FEV1, % predicted (mean, range) 79 (67–101) 92 (66–118) 0.06
OLD (n=) 0 2 0.51
GOLD 1 (n=) 0 1 1
GOLD 2 (n=) 0 1 1
Prior chemotherapy (n=) 2 4 1
Hypercholesterolemia (n=) 2 1 0.53
Hypertension (n=) 2 5 0.68
Diabetes mellitus (n=) 1 3 1
Treatment by statin (n=) 1 5 0.36
Vasodilating treatment (n=) 1 3 1
  1. ED+: endothelial dysfunction; ED: no endothelial dysfunction; FEV1: forced expiratory volume in 1 second; OLD: presence of an obstructive pulmonary disease, defined as post-bronchodilator FEV1/forced vital capacity < 70%.